Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 after Oral Administration to Healthy Adult Male Subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
37
1. Period: INT-2150 2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg
1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg 2. Period: INT-2150
Kukje Pharm
Seongnam-si, South Korea
AUCt
Pharmacokinetic Characteristics
Time frame: One day
Cmax
Pharmacokinetic Characteristics
Time frame: One day
AUC∞
Pharmacokinetic Characteristics
Time frame: One day
tmax
Pharmacokinetic Characteristics
Time frame: One day
t1/2
Pharmacokinetic Characteristics
Time frame: One day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.